oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer
January 2010
Women are hearing that oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer.
A new look at the Women's Health Initiative suggests one-third fewer breast cancers in postmenopausal women taking oral bisphosphonates.
Another observational study from Israel shows a similar benefit.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive